Nasdaq

Evaxion Biotech Advances CMV Vaccine with AI Innovation

Evaxion Biotech (EVAX) has released an update. Evaxion Biotech has unveiled promising preclinical results for its cytomegalovirus vaccine program, EVX-V1, utilizing its AI-Immunology platform to ...
Nasdaq

Evaxion Biotech announces preclinical data for CMV vaccine program EVX-V1

Evaxion Biotech (EVAX) announces new positive preclinical data from its ongoing cytomegalovirus, CMV, vaccine program named EVX-V1. The data will be presented today at the 9th International Conference ...
Business Insider

Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1

Evaxion’s AI-Immunology™ platform has discovered novel CMV antigens that significantly reduce viral infection in preclinical models EVX-V1 is a next-generation, multi-component vaccine program ...
The Boston Globe

Moderna says key study of its CMV vaccine, expected to be its next big win, failed

This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. Moderna said Wednesday afternoon that its ...
Medscape

New Vaccine May Help Prevent Maternal, Congenital CMV Infection

March 19, 2009 — Cytomegalovirus (CMV) glycoprotein B vaccine may help prevent maternal and congenital CMV infection, according to the results of a phase 2, randomized, double-blind, controlled trial ...
Monthly Prescribing Reference

Moderna’s CMV Vaccine Candidate Misses in Late Stage Trial

Findings showed the study did not meet its primary endpoint of preventing CMV infection in seronegative participants. Topline results were announced from a phase 3 study evaluating Moderna’s ...

Moderna’s CMV Vaccine Extension Study Reaches Completion, Setting the Stage for Next Growth Catalyst

Moderna’s latest clinical update centers on a long‑term extension of its cytomegalovirus (CMV) vaccine program, officially titled “A Phase 2, Non-Randomized, Long-Term Extension Study to Evaluate the ...
The Indianapolis Star

Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint

Company to discontinue development of mRNA-1647 in congenital CMV Company will continue to evaluate mRNA-1647 in ongoing Phase 2 trial in bone marrow transplant patients Company does not anticipate ...
News Medical

Novel vaccine approach appears to protect fetus from CMV infection, animal study shows

Long before the Zika virus became a global fear, cytomegalovirus, or CMV, was commonly infecting developing fetuses and causing many of the same brain and developmental impairments. The virus, one of ...

Prenatal infections silently harm babies: How early screening during pregnancy can save lives

Experts say early screening and vaccination can prevent miscarriage, birth defects and lifelong disability. Here's why ...
The Post-Crescent

Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint

CAMBRIDGE, MA / ACCESS Newswire / October 22, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the Company’s ...